{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:17:23Z","timestamp":1777555043158,"version":"3.51.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Dermatitis\u00ae"],"published-print":{"date-parts":[[2014,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The objective of this study was to determine the prevalence of positive patch tests in patients with psoriasis receiving biologics and whether these results differ from those of patients with psoriasis not on biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An institutional review board\u2013approved retrospective chart review was conducted for patients with psoriasis patch tested January 2002\u20132012 at Tufts Medical Center. Patients had a history of psoriasis, psoriatic arthritis, and patch testing as identified by\n                      <jats:italic toggle=\"yes\">International Classification of Diseases, Ninth Revision<\/jats:italic>\n                      codes 696.1, 696.0, and 95044, respectively, in their records. Patients were tested to a modified North American Contact Dermatitis Group standard and cosmetics series. Readings were performed at 48 hours and 72 to 96 hours. The North American Contact Dermatitis Group grading system was used to grade reactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen patients with psoriasis on biologics (cases) and 16 patients with psoriasis not on biologics (control subjects) were studied. The biologics used were ustekinumab (n = 7), etanercept (n = 4), adalimumab (n = 3), and infliximab (n = 1). Eighty percent (12\/15) of cases had at least 1 positive reaction compared with 81% (13\/16) of the control subjects; 67% (10\/15) of cases had 2+ reactions compared with 63% (10\/16) of the control subjects, and 27% (4\/15) of cases had 3+ reactions, compared with 38% (6\/16) of control subjects. These differences were not statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given the limitation of small numbers of patients, biologics do not appear to influence the abilities of patients with psoriasis to mount a positive patch test.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/der.0000000000000056","type":"journal-article","created":{"date-parts":[[2014,7,4]],"date-time":"2014-07-04T08:38:13Z","timestamp":1404463093000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":22,"title":["Patch Test Results in Psoriasis Patients on Biologics"],"prefix":"10.1177","volume":"25","author":[{"given":"Noori","family":"Kim","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, Tufts Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimrat","family":"Notik","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Tufts Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Tufts Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L.","family":"Scheinman","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, Tufts Medical Center, Boston, MA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,8,1]]},"reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.6.3079"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.057"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802206660"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1975.tb05337.x"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1996.tb02309.x"},{"key":"e_1_3_1_7_2","first-page":"96","article-title":"The incidence of allergic contact dermatitis in patients with psoriasis vulgaris","volume":"9","author":"Clark AR","year":"1998","unstructured":"Clark AR, , Sherertz EF. The incidence of allergic contact dermatitis in patients with psoriasis vulgaris. Am J Contact Dermatitis, 1998; 9: 96\u201399.","journal-title":"Am J Contact Dermatitis"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1998.tb05657.x"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1080\/000155502762064566"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09314.x"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.1987.tb02729.x"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-001-0276-9"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.09.036"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.162.1.494"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09400.x"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05505"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700855"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00347.x"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00041.x"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.3.1908"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.16.6367"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2007.04.004"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2004.04.003"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104200"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000339866"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2004.04045.x"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/247553030713a00101"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1088"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.307"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60140-9"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071094"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2721"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062382"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2008.07040"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.2310\/6620.2009.09005"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.003"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.016"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2012.02155.x"},{"key":"e_1_3_1_45_2","unstructured":"Stelara [package insert]. Available at: http:\/\/www.stelarainfo.com\/pdf\/PrescribingInformation.pdf#zoom=100. Accessed April5 2014."},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004273321"},{"key":"e_1_3_1_47_2","unstructured":"Humira. Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm092762.pdf. Accessed April5 2014."},{"key":"e_1_3_1_48_2","unstructured":"Remicade [package insert]. Available at: http:\/\/www.remicade.com\/shared\/product\/remicade\/prescribing-information.pdf. Accessed April4 2014."},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/DER.0b013e3182819c51"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1972.tb01895.x"},{"key":"e_1_3_1_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-1873.2004.00340.x"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00391-6"},{"key":"e_1_3_1_53_2","first-page":"446","article-title":"GATA-3 regulates contact hyperresponsiveness in a murine model of allergic dermatitis","volume":"217","author":"Tamauchi H","year":"2012","unstructured":"Tamauchi H, , Amoh Y, , Itoh M, et al. GATA-3 regulates contact hyperresponsiveness in a murine model of allergic dermatitis. Immunology, 2012; 217: 446\u2013454.","journal-title":"Immunology"},{"key":"e_1_3_1_54_2","doi-asserted-by":"publisher","DOI":"10.1159\/000314372"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05750.x"},{"key":"e_1_3_1_56_2","first-page":"37","article-title":"Contact allergy to nickel: patch test score correlates with IL-5, but not with IFN-gamma nickel-specific secretion by peripheral blood lymphocytes","volume":"16","author":"Czarnobilska E","year":"2009","unstructured":"Czarnobilska E, , Jenner B, , Kaszuba-Zwoinska J, et al. Contact allergy to nickel: patch test score correlates with IL-5, but not with IFN-gamma nickel-specific secretion by peripheral blood lymphocytes. Ann Agric Environ Med, 2009; 16: 37\u201341.","journal-title":"Ann Agric Environ Med"},{"key":"e_1_3_1_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2009.01541.x"}],"container-title":["Dermatitis\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000056","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1097\/DER.0000000000000056","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1097\/DER.0000000000000056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:08:26Z","timestamp":1777399706000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1097\/DER.0000000000000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,1]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8,1]]}},"alternative-id":["10.1097\/DER.0000000000000056"],"URL":"https:\/\/doi.org\/10.1097\/der.0000000000000056","relation":{},"ISSN":["1710-3568","2162-5220"],"issn-type":[{"value":"1710-3568","type":"print"},{"value":"2162-5220","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,1]]}}}